Cargando…
Glycosylated fibronectin point‐of‐care test for diagnosis of pre‐eclampsia in a low‐resource setting: a prospective Southeast Asian population study
OBJECTIVE: To determine the performance of a glycosylated fibronectin (GlyFn) point‐of‐care (POC) test for pre‐eclampsia (PE) in a large Southeast Asian cohort (India) in comparison to previously described biomarkers. DESIGN: A total of 798 pregnant women at ≥20 weeks of gestation were enrolled in a...
Autores principales: | Nagalla, SR, Janaki, V, Vijayalakshmi, AR, Chayadevi, K, Pratibha, D, Rao, PV, Sage, KM, Nair‐Schaef, D, Bean, E, Roberts, CT, Gravett, MG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687275/ https://www.ncbi.nlm.nih.gov/pubmed/32426899 http://dx.doi.org/10.1111/1471-0528.16323 |
Ejemplares similares
-
Glycosylated fibronectin as a first trimester marker for gestational diabetes
por: Alanen, Julia, et al.
Publicado: (2020) -
Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study
por: Huhn, Evelyn A., et al.
Publicado: (2020) -
Placental growth factor testing for suspected pre‐eclampsia: a cost‐effectiveness analysis
por: Duhig, KE, et al.
Publicado: (2019) -
Pravastatin for early‐onset pre‐eclampsia: a randomised, blinded, placebo‐controlled trial
por: Ahmed, A, et al.
Publicado: (2019) -
Should cervical favourability play a role in the decision for labour induction in gestational hypertension or mild pre-eclampsia at term? An exploratory analysis of the HYPITAT trial
por: Tajik, P, et al.
Publicado: (2012)